What makes this call so interesting is that the company just announced earlier this week that its management will present in a fireside chat at the 2012 Deutsche Bank Access BioFEST Conference on December 3, 2012 in Boston. With a focus on hepatitis B and C it seems as though investors are hoping that the company’s pipeline in Phase II studies will have significant upside since Idenix has estimated that more than 170 million people worldwide are chronically infected with HCV.
Shares are up a sharp 13% at $5.13 on the news and the volume is already closing in on 1 million shares after only about an hour of trading. Idenix has a $685 million market cap and shares have a 52-week range of $3.35 to $15.25. Another observation is that the consensus analyst target is already about $7.20 here with a range of $4.00 to $15.00 for the stock.
JON C. OGG
Want to Retire Early? Start Here (Sponsor)
Want retirement to come a few years earlier than you’d planned? Or are you ready to retire now, but want an extra set of eyes on your finances?
Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help you build your plan to retire early. And the best part? The first conversation with them is free.
Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
